Milou Jacobs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Milou Jacobs has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Ellen P. Hart
Centre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, The Netherlands
4 shared publications- Raymund A. C. Roos
Department of Neurology, Leiden University Medical Center, The Netherlands
3 shared publications - Emma M. Coppen
Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands
2 shared publications Geert Jan Groeneveld
Centre for Human Drug Research, Zernikedreef 8, 2333 CL Leiden, The Netherlands
2 shared publicationsRaymund A. C. Roos
A Department of Neurology , Leiden University Medical Center , Leiden , The Netherlands
2 shared publicationsRaymund A.C. Roos
Department of Neurology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
2 shared publications
Latest Publications
- 5 September 2021
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 92 (Suppl 1) , A53.1-A53
J01 Triheptanoin is associated with clinical stability and decreased caudate atrophy in huntington disease
Objective To assess the efficacy of triheptanoin, a medium chain triglyceride with an odd number of carbons that targets the Krebs cycle, on key brain imaging and clinical measures in HD. Background We previously showed that energy deficit in HD is associated with increased substrate requirements for the Krebs cycle. Using brain MR spectroscopy, we then demonstrated that triheptanoin can restore a normal brain energetic profile in HD patients. Methods We conducted a 6-month randomized controlled bi-centric trial (Paris and Leiden) called TRIHEP3 (NCT02453061), comparing triheptanoin 1g/kg/day vs placebo in 100 patients (ratio 1/1) at an early stage of HD, followed by a 6-month open label phase. Patients could then opt for a one-year extension study. To compare triheptanoin versus placebo over one year, we used the placebo arm of a one-year randomized controlled trial (NCT02336633), conducted in parallel with identical methods, in HD patients with similar clinical characteristics (age, UHDRS-TMS, CAG). Results 86 patients completed the one-year TRIHEP3 study and 42 completed the consecutive 12-month extension. Triheptanoin was well tolerated. We saw no difference in cBSI at 6 months between triheptanoin and placebo. TMS at 12 months tended to stabilize in patients treated with triheptanoin for one year (mean 0.6 ± 5.1) compared to patients treated for 6 months (2.5 ± 4.5) (p= 0.072), with a significant difference between 6 and 12 months (-0.7 ± 3.9 vs 1.9 ± 4.7, p= 0.024). Diffusion tensor imaging showed improved fiber trophicity at 24 months in both groups. Compared to the external placebo control group, at one year, TMS confirmed clinical stability in patients treated with triheptanoin (2.6 ± 4.6 vs 0.6 ± 5.1, p= 0.057) and caudate atrophy was significantly less (-3% vs -6.7% compared to baseline, p< 0.001) (figure 1). Conclusion These results showed that treatment with triheptanoin was associated with clinical stability and decreased caudate atrophy in HD.
- 5 September 2021
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 92 (Suppl 1) , A53.1-A53
J01 Triheptanoin is associated with clinical stability and decreased caudate atrophy in huntington disease
Objective To assess the efficacy of triheptanoin, a medium chain triglyceride with an odd number of carbons that targets the Krebs cycle, on key brain imaging and clinical measures in HD. Background We previously showed that energy deficit in HD is associated with increased substrate requirements for the Krebs cycle. Using brain MR spectroscopy, we then demonstrated that triheptanoin can restore a normal brain energetic profile in HD patients. Methods We conducted a 6-month randomized controlled bi-centric trial (Paris and Leiden) called TRIHEP3 (NCT02453061), comparing triheptanoin 1g/kg/day vs placebo in 100 patients (ratio 1/1) at an early stage of HD, followed by a 6-month open label phase. Patients could then opt for a one-year extension study. To compare triheptanoin versus placebo over one year, we used the placebo arm of a one-year randomized controlled trial (NCT02336633), conducted in parallel with identical methods, in HD patients with similar clinical characteristics (age, UHDRS-TMS, CAG). Results 86 patients completed the one-year TRIHEP3 study and 42 completed the consecutive 12-month extension. Triheptanoin was well tolerated. We saw no difference in cBSI at 6 months between triheptanoin and placebo. TMS at 12 months tended to stabilize in patients treated with triheptanoin for one year (mean 0.6 ± 5.1) compared to patients treated for 6 months (2.5 ± 4.5) (p= 0.072), with a significant difference between 6 and 12 months (-0.7 ± 3.9 vs 1.9 ± 4.7, p= 0.024). Diffusion tensor imaging showed improved fiber trophicity at 24 months in both groups. Compared to the external placebo control group, at one year, TMS confirmed clinical stability in patients treated with triheptanoin (2.6 ± 4.6 vs 0.6 ± 5.1, p= 0.057) and caudate atrophy was significantly less (-3% vs -6.7% compared to baseline, p< 0.001) (figure 1). Conclusion These results showed that treatment with triheptanoin was associated with clinical stability and decreased caudate atrophy in HD.
- 1 March 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 60, 64-69
Predictors of simulated driving performance in Huntington's disease
- 1 March 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 60, 64-69
Predictors of simulated driving performance in Huntington's disease
- 1 January 2019
- Published by Elsevier in Transportation Research Part F: Traffic Psychology and Behaviour
- Vol. 60, 499-504
Comparable rates of simulator sickness in Huntington’s disease and healthy individuals
- 1 January 2019
- Published by Elsevier in Transportation Research Part F: Traffic Psychology and Behaviour
- Vol. 60, 499-504
Comparable rates of simulator sickness in Huntington’s disease and healthy individuals
- Open Access
- 1 October 2018
- Published by Taylor & Francis in Traffic Injury Prevention
- Vol. 19 (7) , 708-714
Altered driving performance of symptomatic Huntington’s disease gene carriers in simulated road conditions
Objective: In clinical practice, patients with Huntington’s disease (HD) often decide to solely drive in their own familiar neighborhoods and not on a motorway or in an unknown area. The aim of the study was to identify differences in driving performance between HD gene carriers and healthy individuals in simulated urban and motorway environments. Methods: This cross-sectional study included 87 participants (28 premanifest HD, 30 manifest HD, 29 controls). All participants were active drivers and were assessed using a driving simulator, a driving history questionnaire, and the Unified Huntington’s Disease Rating Scale. The driving simulator session included urban and motorway scenarios. Analysis of variance and Kruskal-Wallis tests were used to compare urban and motorway driving across all 3 groups. Results: Manifest HD drove slower compared to controls and premanifest HD when speed limits increased (80 and 100 km/h) and they had a less steady speed compared to premanifest HD on the motorway and in a 30 km/h zone. Manifest HD also had a larger standard deviation of the lateral position (i.e., more weaving of the car/less vehicle control) compared to controls and premanifest HD on the motorway. Conclusions: Manifest HD drive more cautious in a driving simulator when speed limits increase compared to premanifest HD and controls and they have less vehicle control on the motorway. The driving simulator parameters are able to discriminate between manifest HD and healthy individuals, so a driving simulator seems a feasible tool to use when investigating changes in driving in manifest HD.
- 1 October 2018
- Published by Taylor & Francis in Traffic Injury Prevention
- Vol. 19 (7) , 708-714
Open AccessAltered driving performance of symptomatic Huntington’s disease gene carriers in simulated road conditions
Objective: In clinical practice, patients with Huntington’s disease (HD) often decide to solely drive in their own familiar neighborhoods and not on a motorway or in an unknown area. The aim of the study was to identify differences in driving performance between HD gene carriers and healthy individuals in simulated urban and motorway environments. Methods: This cross-sectional study included 87 participants (28 premanifest HD, 30 manifest HD, 29 controls). All participants were active drivers and were assessed using a driving simulator, a driving history questionnaire, and the Unified Huntington’s Disease Rating Scale. The driving simulator session included urban and motorway scenarios. Analysis of variance and Kruskal-Wallis tests were used to compare urban and motorway driving across all 3 groups. Results: Manifest HD drove slower compared to controls and premanifest HD when speed limits increased (80 and 100 km/h) and they had a less steady speed compared to premanifest HD on the motorway and in a 30 km/h zone. Manifest HD also had a larger standard deviation of the lateral position (i.e., more weaving of the car/less vehicle control) compared to controls and premanifest HD on the motorway. Conclusions: Manifest HD drive more cautious in a driving simulator when speed limits increase compared to premanifest HD and controls and they have less vehicle control on the motorway. The driving simulator parameters are able to discriminate between manifest HD and healthy individuals, so a driving simulator seems a feasible tool to use when investigating changes in driving in manifest HD.
- 1 July 2018
- Published by American Psychiatric Association Publishing in The Journal of Neuropsychiatry and Clinical Neurosciences
- Vol. 30 (3) , 188-193
Cognitive Performance and Apathy Predict Unemployment in Huntington’s Disease Mutation Carriers
Unemployment is common for those with Huntington’s disease (HD), a genetic neurodegenerative disorder, and affects patients’ quality of life. HD is characterized by motor disturbances, cognitive dysfunction, and psychiatric symptoms. The purpose of this article was to determine which clinical signs of HD are predictive of unemployment. Data for employed (N=114) and unemployed (N=106) HD mutation carriers were used to investigate group differences. Univariate logistic regression analyses, adjusted for age and gender, were performed to determine individual predictors of unemployment. Subsequently, a multivariate logistic regression analysis was performed, entering all significant results from the univariate analyses into one fully adjusted model to determine the strongest predictors. HD mutation carriers with lower cognitive performances and higher apathy scores were more likely to be unemployed than were HD mutation carriers with higher cognitive scores and no signs of apathy. Motor functioning was an independent predictor of unemployment but was not associated with unemployment in the fully adjusted model. Cognitive impairments, especially in the executive domain, and apathy were independent determinants of unemployment in HD mutation carriers. Motor disturbances, the clinical hallmark of HD, did not appear to be the most important predictor for work cessation. These results should be taken into consideration in clinical practice when evaluating HD patients’ ability to work.
- 1 July 2018
- Published by American Psychiatric Association Publishing in The Journal of Neuropsychiatry and Clinical Neurosciences
- Vol. 30 (3) , 188-193
Cognitive Performance and Apathy Predict Unemployment in Huntington’s Disease Mutation Carriers
Unemployment is common for those with Huntington’s disease (HD), a genetic neurodegenerative disorder, and affects patients’ quality of life. HD is characterized by motor disturbances, cognitive dysfunction, and psychiatric symptoms. The purpose of this article was to determine which clinical signs of HD are predictive of unemployment. Data for employed (N=114) and unemployed (N=106) HD mutation carriers were used to investigate group differences. Univariate logistic regression analyses, adjusted for age and gender, were performed to determine individual predictors of unemployment. Subsequently, a multivariate logistic regression analysis was performed, entering all significant results from the univariate analyses into one fully adjusted model to determine the strongest predictors. HD mutation carriers with lower cognitive performances and higher apathy scores were more likely to be unemployed than were HD mutation carriers with higher cognitive scores and no signs of apathy. Motor functioning was an independent predictor of unemployment but was not associated with unemployment in the fully adjusted model. Cognitive impairments, especially in the executive domain, and apathy were independent determinants of unemployment in HD mutation carriers. Motor disturbances, the clinical hallmark of HD, did not appear to be the most important predictor for work cessation. These results should be taken into consideration in clinical practice when evaluating HD patients’ ability to work.
- 1 January 2018
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 46, 56-61
Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease
- 1 January 2018
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 46, 56-61
Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease
- Open Access
- 19 April 2017
- Published by Springer Nature in Journal of Neurology
- Vol. 264 (8) , 1678-1696
Driving with a neurodegenerative disorder: an overview of the current literature
Driving is important for employment, social activities, and for the feeling of independence. The decision to cease driving affects the quality of life and has been associated with reduced mobility, social isolation, and sadness. Patients with neurodegenerative disorders can experience difficulties while driving due to their cognitive, motor, and behavioral impairments. The aim of this review is to summarize the available literature on changes in driving competence and behavior in patients with neurodegenerative disorders, with a particular focus on Huntington’s (HD), Parkinson’s (PD), and Alzheimer’s disease (AD). A systematic literature search was conducted in the PubMed/Medline database. Studies using on-road or simulated driving assessments were examined in this review. In addition, studies investigating the association between cognitive functioning and driving were included. The review identified 70 studies. Only a few publications were available on HD (n = 7) compared to PD (n = 32) and AD (n = 31). This review revealed that driving is impaired in patients with neurodegenerative disorders on all levels of driving competence. The errors most commonly committed were on the tactical level including lane maintenance and lane changing. Deficits in executive functioning, attention, and visuospatial abilities can partially predict driving competence, and the performance on neuropsychological tests might be useful when discussing potential driving cessation. Currently, there is no gold standard to assess driving ability using clinical measures such as neuropsychological assessments, so more studies are necessary to detect valid screening tools and develop useful and reliable evidence-based guidelines.
- 19 April 2017
- Published by Springer Nature in Journal of Neurology
- Vol. 264 (8) , 1678-1696
Open AccessDriving with a neurodegenerative disorder: an overview of the current literature
Driving is important for employment, social activities, and for the feeling of independence. The decision to cease driving affects the quality of life and has been associated with reduced mobility, social isolation, and sadness. Patients with neurodegenerative disorders can experience difficulties while driving due to their cognitive, motor, and behavioral impairments. The aim of this review is to summarize the available literature on changes in driving competence and behavior in patients with neurodegenerative disorders, with a particular focus on Huntington’s (HD), Parkinson’s (PD), and Alzheimer’s disease (AD). A systematic literature search was conducted in the PubMed/Medline database. Studies using on-road or simulated driving assessments were examined in this review. In addition, studies investigating the association between cognitive functioning and driving were included. The review identified 70 studies. Only a few publications were available on HD (n = 7) compared to PD (n = 32) and AD (n = 31). This review revealed that driving is impaired in patients with neurodegenerative disorders on all levels of driving competence. The errors most commonly committed were on the tactical level including lane maintenance and lane changing. Deficits in executive functioning, attention, and visuospatial abilities can partially predict driving competence, and the performance on neuropsychological tests might be useful when discussing potential driving cessation. Currently, there is no gold standard to assess driving ability using clinical measures such as neuropsychological assessments, so more studies are necessary to detect valid screening tools and develop useful and reliable evidence-based guidelines.
- Open Access
- 19 July 2016
- Published by Springer Nature in Journal of Neurology
- Vol. 263 (10) , 2080-2085
Progression of motor subtypes in Huntington’s disease: a 6-year follow-up study
The objective of this study is to investigate the progression of predominantly choreatic and hypokinetic-rigid signs in Huntington’s disease (HD) and their relationship with cognitive and general functioning over time. The motor signs in HD can be divided into predominantly choreatic and hypokinetic-rigid subtypes. It has been reported in cross-sectional studies that predominantly choreatic HD patients perform better on functional and cognitive assessments compared to predominantly hypokinetic-rigid HD patients. The course of these motor subtypes and their clinical profiles has not been investigated longitudinally. A total of 4135 subjects who participated in the European HD Network REGISTRY study were included and classified at baseline as either predominantly choreatic (n = 891), hypokinetic-rigid (n = 916), or mixed-motor (n = 2328), based on a previously used method. The maximum follow-up period was 6 years. The mixed-motor group was not included in the analyses. Linear mixed models were constructed to investigate changes in motor subtypes over time and their relationship with cognitive and functional decline. Over the 6-year follow-up period, the predominantly choreatic group showed a significant decrease in chorea, while hypokinetic-rigid symptoms slightly increased in the hypokinetic-rigid group. On the Total Functional Capacity, Stroop test, and Verbal fluency task the rate of change over time was significantly faster in the predominantly choreatic group, while on all other clinical assessments the decline was comparable for both groups. Our results suggest that choreatic symptoms decrease over time, whereas hypokinetic-rigid symptoms slightly increase in a large cohort of HD patients. Moreover, different motor subtypes can be related to different clinical profiles.
- 19 July 2016
- Published by Springer Nature in Journal of Neurology
- Vol. 263 (10) , 2080-2085
Open AccessProgression of motor subtypes in Huntington’s disease: a 6-year follow-up study
The objective of this study is to investigate the progression of predominantly choreatic and hypokinetic-rigid signs in Huntington’s disease (HD) and their relationship with cognitive and general functioning over time. The motor signs in HD can be divided into predominantly choreatic and hypokinetic-rigid subtypes. It has been reported in cross-sectional studies that predominantly choreatic HD patients perform better on functional and cognitive assessments compared to predominantly hypokinetic-rigid HD patients. The course of these motor subtypes and their clinical profiles has not been investigated longitudinally. A total of 4135 subjects who participated in the European HD Network REGISTRY study were included and classified at baseline as either predominantly choreatic (n = 891), hypokinetic-rigid (n = 916), or mixed-motor (n = 2328), based on a previously used method. The maximum follow-up period was 6 years. The mixed-motor group was not included in the analyses. Linear mixed models were constructed to investigate changes in motor subtypes over time and their relationship with cognitive and functional decline. Over the 6-year follow-up period, the predominantly choreatic group showed a significant decrease in chorea, while hypokinetic-rigid symptoms slightly increased in the hypokinetic-rigid group. On the Total Functional Capacity, Stroop test, and Verbal fluency task the rate of change over time was significantly faster in the predominantly choreatic group, while on all other clinical assessments the decline was comparable for both groups. Our results suggest that choreatic symptoms decrease over time, whereas hypokinetic-rigid symptoms slightly increase in a large cohort of HD patients. Moreover, different motor subtypes can be related to different clinical profiles.